Deepak L Bhatt, Keith A A Fox, Werner Hacke, Peter B Berger, Henry R Black, William E Boden, Patrice Cacoub, Eric A Cohen, Mark A Creager, J Donald Easton, Marcus D Flather, Steven M Haffner, Christian W Hamm, Graeme J Hankey, S Claiborne Johnston, Koon-Hou Mak, Jean-Louis Mas, Gilles Montalescot, Thomas A Pearson, P Gabriel Steg, Steven R Steinhubl, Michael A Weber, Danielle M Brennan, Liz Fabry-Ribaudo, Joan Booth, Eric J Topol
BACKGROUND: Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events. METHODS: We randomly assigned 15,603 patients with either clinically evident cardiovascular disease or multiple risk factors to receive clopidogrel (75 mg per day) plus low-dose aspirin (75 to 162 mg per day) or placebo plus low-dose aspirin and followed them for a median of 28 months. The primary efficacy end point was a composite of myocardial infarction, stroke, or death from cardiovascular causes...
April 20, 2006: New England Journal of Medicine